Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma.
| Revenue (Most Recent Fiscal Year) | $239.44M |
| Net Income (Most Recent Fiscal Year) | $-80.45M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 142.57 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.62 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.63 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -6.74% |
| Net Margin (Trailing 12 Months) | -7.24% |
| Return on Equity (Trailing 12 Months) | 3.31% |
| Return on Assets (Trailing 12 Months) | 2.55% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.12 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.31 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.09 |
| Inventory Turnover (Trailing 12 Months) | 1.27 |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.08 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.29 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.70 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.43 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Common Shares Outstanding | 49.79M |
| Free Float | 29.92M |
| Market Capitalization | $1.63B |
| Average Volume (Last 20 Days) | 1.03M |
| Beta (Past 60 Months) | 1.20 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 39.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 96.70% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |